Meyer, Jeppe http://orcid.org/0000-0001-9249-5212
Alstrup, Morten
Rasmussen, Line J. H.
Schultz, Martin
Ladelund, Steen
Haupt, Thomas H.
Tingleff, Jens
Iversen, Kasper
Eugen-Olsen, Jesper
Funding for this research was provided by:
Virogates A/S
Article History
Received: 21 September 2017
Accepted: 15 January 2018
First Online: 1 February 2018
Ethics approval and consent to participate
: This retrospective registry-based study was approved by the Danish Health and Medicines authority (reference no. 3–3013-1061/1). All processing of personal data followed national guidelines, and the project was approved by the Danish Data Protection Agency (reference no. HVH-2014-018, 02767). According to Danish legislation, patient consent is not necessary for registry-based research if approval has been obtained from the Danish Health and Medicines Authority.
: Not applicable.
: JM, MS, MA, and LJHR have received funding for travel from ViroGates A/S, Denmark, the company that produces the suPARnostic assays. MS is supported from a project grant given to the Department of Cardiology, Copenhagen University Hospital Herlev, from ViroGates A/S outside the submitted work. JE-O is a named inventor on patents on suPAR and prognosis. The patents are owned by Copenhagen University Hospital Hvidovre, Denmark, and licensed to ViroGates A/S. JE-O is a co-founder, shareholder, and CSO of ViroGates A/S.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.